65 related articles for article (PubMed ID: 25022336)
1. Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.
Eberstål S; Fritzell S; Sandén E; Visse E; Darabi A; Siesjö P
J Neuroimmunol; 2014 Sep; 274(1-2):161-7. PubMed ID: 25022336
[TBL] [Abstract][Full Text] [Related]
2. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells.
Smith KE; Fritzell S; Badn W; Eberstål S; Janelidze S; Visse E; Darabi A; Siesjö P
Int J Cancer; 2009 Feb; 124(3):630-7. PubMed ID: 18972433
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
[TBL] [Abstract][Full Text] [Related]
4. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
Ströjby S; Eberstål S; Svensson A; Fritzell S; Bexell D; Siesjö P; Darabi A; Bengzon J
J Neuroimmunol; 2014 Sep; 274(1-2):240-3. PubMed ID: 25086876
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors.
Eberstål S; Badn W; Fritzell S; Esbjörnsson M; Darabi A; Visse E; Siesjö P
Cancer Immunol Immunother; 2012 Aug; 61(8):1191-9. PubMed ID: 22213142
[TBL] [Abstract][Full Text] [Related]
6. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
Smith KE; Janelidze S; Visse E; Badn W; Salford L; Siesjö P; Darabi A
Int J Cancer; 2007 Jan; 120(1):75-80. PubMed ID: 17044023
[TBL] [Abstract][Full Text] [Related]
7. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
Janelidze S; Bexell D; Badn W; Darabi A; Smith KE; Fritzell S; Gunnarsson S; Milos P; Bengzon J; Salford LG; Siesjö P; Visse E
J Immunother; 2009; 32(6):593-601. PubMed ID: 19483650
[TBL] [Abstract][Full Text] [Related]
8. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
9. Postimmunization with IFN-gamma-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors.
Badn W; Visse E; Darabi A; Smith KE; Salford LG; Siesjö P
J Immunol; 2007 Sep; 179(6):4231-8. PubMed ID: 17785863
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-gamma-secreting glioma cells.
Badn W; Hegardt P; Fellert MA; Darabi A; Esbjörnsson M; Smith KE; Janelidze S; Salford LG; Visse E; Siesjö P
Scand J Immunol; 2007 Mar; 65(3):289-97. PubMed ID: 17309784
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
12. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
13. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors.
Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A
Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199
[TBL] [Abstract][Full Text] [Related]
14. IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models.
Fritzell S; Eberstål S; Sandén E; Visse E; Darabi A; Siesjö P
J Neuroimmunol; 2013 May; 258(1-2):91-5. PubMed ID: 23528658
[TBL] [Abstract][Full Text] [Related]
15. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
DeLong P; Tanaka T; Kruklitis R; Henry AC; Kapoor V; Kaiser LR; Sterman DH; Albelda SM
Cancer Res; 2003 Nov; 63(22):7845-52. PubMed ID: 14633712
[TBL] [Abstract][Full Text] [Related]
16. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
17. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.
Siesjö P; Visse E; Sjögren HO
J Immunother Emphasis Tumor Immunol; 1996 Sep; 19(5):334-45. PubMed ID: 8941873
[TBL] [Abstract][Full Text] [Related]
18. Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells.
Volovitz I; Marmor Y; Azulay M; Machlenkin A; Goldberger O; Mor F; Slavin S; Ram Z; Cohen IR; Eisenbach L
J Immunol; 2011 Nov; 187(10):5452-62. PubMed ID: 21998458
[TBL] [Abstract][Full Text] [Related]
19. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.
Akasaki Y; Kikuchi T; Homma S; Abe T; Kofe D; Ohno T
J Immunother; 2001; 24(2):106-13. PubMed ID: 11265767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
